Drug Trial Radar · NCT06147414
Development of Non-Invasive Prenatal Diagnosis for Single Gene Disorders
Last checked: Nov 20, 2026Latest source record: Oct 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
550
Planned (sponsor's estimate)
Start
Oct 23, 2024
Primary completion
May 2027
Study completion Jun 2028
Sponsor
- Lead sponsor
- Assistance Publique - Hôpitaux de ParisAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- URC-CIC Paris Descartes Necker Cochin
- First posted
- Nov 27, 2023
Design
- Study type
- Observational
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Cell-free fetal DNA (cffDNA) is present in the maternal blood from the early first trimester of gestation and makes up 5%-20% of the total circulating cell-free DNA (cfDNA) in maternal plasma. Its presence in maternal plasma has allowed development of noninvasive prenatal diagnosis for single-gene disorders (SGD-NIPD). This can be performed from 9 weeks of amenorrhea and offers an early, safe and accurate definitive diagnosis without the miscarriage risk associated with invasive procedures. One of the major difficulties is distinguishing fetal genotype in the high background of maternal cfDNA, which leads to several technical and analytical challenges. Besides, unlike noninvasive prenatal testing for aneuploidy, NIPD for monogenic diseases represent a smaller market opportunity, and many cases must be provided on a bespoke, patient- or disease-specific basis. As a result, implementation of SGD-NIPD remained sparse, with most testing being delivered in a research setting. The present project aims to take advantage of the unique French collaborative network to make SGD-NIPD possible for theoretically any monogenic disorder and any family.
Conditions
- Invasive PreNatal Diagnosis in a Context of Family History of Single-gene Disorders, Including
- Sickle Cell Disease
- Cystic Fibrosis
- Fragile X Syndrome
- Proximal Spinal Muscular Atrophy
- Myotonic Dystrophy
- Muscular Dystrophy, Duchenne
- Muscular Dystrophy, Becker
- Neurofibromatosis-Noonan Syndrome
- Huntington Disease
- Hemophilia A
- Hemophilia B
- MODY2 Diabetes
- X-Linked Hydrocephalus
- Autosomal Recessive Polycystic Kidney Disease
Interventions
Blood sampleBiological
A blood sample (50 ml) will be taken in care of prenatal diagnosis and 40 ml will be used for study. The 40 mL of blood needed for the research will be collected on BCT tubes (4 tubes). During the study, in centers, the plasma samples will be stored at room temperature and will be sent to the laboratory within 24 hours (no centrifugation in centers). The plasma samples will be then temporarily stored at -80°C in each co-investigating laboratory under the supervision of lab supervisor until the analysis. cfDNA will be extracted from the whole plasma sample before each sequencing run and stored à +4°C until the cfDNA sequencing.
Primary outcomes
What the sponsor says the trial is designed to measure.
- % of affected/unaffected fetuses that were correctly classified as affected/unaffectedTime frame: 1 day
- % of inconclusive resultsTime frame: 1 day
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Hôpital Cochin, Maternité Port-Royal, service de Gynécologie obstétrique
Paris, France · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.